Company Overview
About Tessera Therapeutics
Tessera Therapeutics is a genomic medicine company founded in 2018 by Jacob Rubens, Brian Goodman, and colleagues at Flagship Pioneering (the life sciences venture creation firm behind Moderna) and headquartered in Cambridge, Massachusetts. The company is pioneering Gene Writing — a platform technology that uses mobile genetic elements (specifically RNA-guided integrases derived from retrotransposons) to write large DNA sequences directly into the human genome at targeted sites, without requiring double-strand DNA breaks. This approach is designed to overcome key limitations of first-generation gene editing technologies: CRISPR-Cas9 creates double-strand breaks that can introduce unintended mutations, and current gene editing tools are largely limited to small sequence corrections or knockouts rather than full gene insertions.
Business Model & Competitive Advantage
Gene Writing has the potential to address genetic diseases that require insertion of complete functional gene sequences — conditions such as hemoglobinopathies, metabolic liver diseases, and other monogenic disorders where gene correction rather than disruption is required for a therapeutic effect. Tessera raised $230M+ in total funding including a $100M Series B led by GV (Google''s life sciences venture arm), Northpond Ventures, and Foresite Capital, with additional investors including Casdin Capital. The company has published peer-reviewed research on Gene Writing in Nature and other journals, validating its scientific approach to a preclinical stage.
Competitive Landscape 2025–2026
Tessera competes in the next-generation genomic medicine space alongside Arbor Biotechnologies, Prime Medicine (which uses Prime Editing, another approach to precision genome editing without double-strand breaks), and Beam Therapeutics (base editing). Each company represents a distinct technological approach to writing DNA sequence changes into the genome more precisely than CRISPR. Tessera''s differentiation is the size of DNA it can write — Gene Writing can potentially insert sequences kilobases in length, whereas base editing and prime editing are optimized for smaller corrections. This positions Tessera for diseases that require full gene replacement rather than point mutation correction.
Key Differentiators
Emerging Innovator
Tessera Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Tessera Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Tessera Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Tessera Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Tessera Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →